Association between time to treatment and outcome in branch retinal vein occlusion.
Humans
Retinal Vein Occlusion
/ drug therapy
Male
Retrospective Studies
Visual Acuity
Aged
Female
Angiogenesis Inhibitors
/ administration & dosage
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Time-to-Treatment
/ statistics & numerical data
Intravitreal Injections
Follow-Up Studies
Tomography, Optical Coherence
/ methods
Aged, 80 and over
Treatment Outcome
Ranibizumab
/ administration & dosage
Fluorescein Angiography
/ methods
Middle Aged
Bevacizumab
/ administration & dosage
Time Factors
Fundus Oculi
Anti-vascular endothelial growth factor therapy
Branch retinal vein occlusion
Central macular thickness
Pro re nata therapy
Visual acuity changes
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
25 Aug 2024
25 Aug 2024
Historique:
received:
14
05
2024
accepted:
29
07
2024
medline:
26
8
2024
pubmed:
26
8
2024
entrez:
25
8
2024
Statut:
epublish
Résumé
To investigate the association between the time from onset to initial treatment and changes in visual acuity or the number of treatments in patients with branch retinal vein occlusion (BVO). Retrospective. Thirty-nine eyes of 39 consecutive patients with untreated acute-phase BVO who visited the University of Tokyo Hospital and were followed up for at least one year were included. The patients were initially treated with anti-vascular endothelial growth factor (VEGF) therapy and additional pro re nata therapy within six months of onset. The patients were classified according to the time from disease onset to the first treatment (group A: 28 days or less, group B: over 28 days). The mean (SD) age was 73 ± 8 years, and 19 patients were male. The mean (SD) time to the first treatment was 31.6 ± 17.9 days. The mean (SD) logMAR visual acuity at first treatment was 0.37 ± 0.30. After 12 months of treatment, the mean (SD) logMAR change was - 0.15 ± 0.23, and the mean number (SD) of treatments was 3.1 ± 1.7. No significant association was observed between the timing of treatment initiation and changes in logMAR visual acuity. Patients in group A and central macular thickness at the initial visit were independently associated with the greater number of treatments at one year (p = 0.03 and p = 0.01, respectively). At one year, the time between onset and the start of anti-VEGF therapy for BVO was not associated with subsequent visual acuity changes. Meanwhile, it may have significant association with the number of treatments.
Identifiants
pubmed: 39182206
doi: 10.1007/s10792-024-03272-w
pii: 10.1007/s10792-024-03272-w
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Vascular Endothelial Growth Factor A
0
Ranibizumab
ZL1R02VT79
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
353Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY (2010) International eye disease consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117(2):313–319. https://doi.org/10.1016/j.ophtha.2009.07.017
doi: 10.1016/j.ophtha.2009.07.017
pubmed: 20022117
Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, Nguyen HP, Wang JJ, Wong TY (2010) Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117(6):1113–1123. https://doi.org/10.1016/j.ophtha.2010.01.058
doi: 10.1016/j.ophtha.2010.01.058
pubmed: 20430446
David G, Bobby T, Caroline B, Andrea R (2023) Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion. Int Ophthalmol 43(11):4105–4110. https://doi.org/10.1007/s10792-023-02811-1
doi: 10.1007/s10792-023-02811-1
Francesco P, Ahmed ME, Tarek RE (2019) Outcome of “treat and monitor” regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. Int Ophthalmol 39(1):145–153. https://doi.org/10.1007/s10792-017-0798-6
doi: 10.1007/s10792-017-0798-6
Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A; RETAIN Study Group (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121:209–219. https://doi.org/10.1016/j.ophtha.2013.08.038
doi: 10.1016/j.ophtha.2013.08.038
Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119:802–809. https://doi.org/10.1016/j.ophtha.2011.12.005
doi: 10.1016/j.ophtha.2011.12.005
pubmed: 22301066
Yilmaz T, Cordero-Coma M (2012) Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review. Graefes Arch Clin Exp Ophthalmol 250:787–793. https://doi.org/10.1007/s00417-012-2016-6
doi: 10.1007/s00417-012-2016-6
pubmed: 22539192
Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND (2009) Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina 29:511–515. https://doi.org/10.1097/iae.0b013e318195ca65
doi: 10.1097/iae.0b013e318195ca65
pubmed: 19174717
Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA (2016) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 123(2):330–336. https://doi.org/10.1016/j.ophtha.2015.09.035
doi: 10.1016/j.ophtha.2015.09.035
pubmed: 26522708
Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG; BRAVO Investigators (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102-1112.e1. https://doi.org/10.1016/j.ophtha.2010.02.021
doi: 10.1016/j.ophtha.2010.02.021
Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(8):1594–1602. https://doi.org/10.1016/j.ophtha.2011.02.022
doi: 10.1016/j.ophtha.2011.02.022
pubmed: 21684606
Wei W, Weisberger A, Zhu L, Cheng Y, Liu C; BLOSSOM Study Group (2020) Efficacy and safety of ranibizumab in asian patients with branch retinal vein occlusion: results from the randomized BLOSSOM study. Ophthalmol Retina 4(1):57–66. https://doi.org/10.1016/j.oret.2019.08.001
doi: 10.1016/j.oret.2019.08.001
Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, Gupta AD, Wenzel A, Pearce I; BRIGHTER Study Group (2017) Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology 124(12):1778–1787. https://doi.org/10.1016/j.ophtha.2017.06.027
doi: 10.1016/j.ophtha.2017.06.027
Ehlken C, Helms M, Böhringer D, Agostini HT, Stahl A (2017) Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol 12:13–20. https://doi.org/10.2147/opth.s151611
doi: 10.2147/opth.s151611
pubmed: 29339917
pmcid: 5745150
Ang JL, Ah-Moye S, Kim LN, Nguyen V, Hunt A, Barthelmes D, Gillies MC, Mehta H (2020) A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion. Eye 34(10):1770–1796. https://doi.org/10.1038/s41433-020-0861-9
doi: 10.1038/s41433-020-0861-9
pubmed: 32313172
pmcid: 7608462
Thach AB, Yau L, Hoang C, Tuomi L (2014) Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology 121(5):1059–1066. https://doi.org/10.1016/j.ophtha.2013.11.022
doi: 10.1016/j.ophtha.2013.11.022
pubmed: 24424249
Xiong K, Gong X, Li W, Yuting L, Meng J, Wang L, Wang W, Wenyong H (2021) Comparison of macular thickness measurements using swept-source and spectral-domain optical coherence tomography in healthy and diabetic subjects. Curr Eye Res 46(10):1567–1573. https://doi.org/10.1080/02713683.2021.1908566
doi: 10.1080/02713683.2021.1908566
pubmed: 33879001
Honda T, Chen S, Hata J, Yoshida D, Hirakawa Y, Furuta Y, Shibata M, Sakata S, Kitazono T, Ninomiya T (2022) Development and validation of a risk prediction model for atherosclerotic cardiovascular disease in japanese adults: the hisayama study. J Atheroscler Thromb 29(3):345–361. https://doi.org/10.5551/jat.61960
doi: 10.5551/jat.61960
pubmed: 33487620
Sakanishi Y, Lee A, Usui-Ouchi A, Ito R, Ebihara N (2016) Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab. OPTH 10:1161–1165. https://doi.org/10.2147/opth.s107594
doi: 10.2147/opth.s107594
Matsui Y, Imamura K, Chujo S, Mase Y, Matsubara H, Sugimoto M, Kawanaka H, Kondo M (2022) Which explanatory variables contribute to the classification of good visual acuity over time in patients with branch retinal vein occlusion with macular edema using machine learning? J Clin Med 11(13):3903. https://doi.org/10.3390/jcm11133903
doi: 10.3390/jcm11133903
pubmed: 35807188
pmcid: 9267411
Bressler SB, Odia I, Maguire MG, Dhoot DS, Glassman AR, Jampol LM, Marcus DM, Solomon SD, Sun JK; Diabetic Retinopathy Clinical Research Network (2019) Factors associated with visual acuity and central subfield thickness changes when treating diabetic macular edema with anti-vascular endothelial growth factor therapy: an exploratory analysis of the protocol t randomized clinical trial. JAMA Ophthalmol 137:382–390. https://doi.org/10.1001/jamaophthalmol.2018.6786
doi: 10.1001/jamaophthalmol.2018.6786
Iida-Miwa Y, Muraoka Y, Iida Y, Ooto S, Murakami T, Suzua K, Tsujikawa A (2019) Branch retinal vein occlusion: treatment outcomes according to the retinal nonperfusion area, clinical subtype, and crossing pattern. Sci Rep 9:6569. https://doi.org/10.1038/s41598-019-42982-5
doi: 10.1038/s41598-019-42982-5
pubmed: 31024035
pmcid: 6483995
Sen P, Gurudas S, Ramu J, Patrao N, Chandra S, Rasheed R, Nicholson L, Peto T, Sivaprasad S, Hykin P (2021) Predictors of visual acuity outcomes after anti-vascular endothelial growth factor treatment for macular edema secondary to central retinal vein occlusion. Oph Retina 5:1115–1124. https://doi.org/10.1016/j.oret.2021.02.008
doi: 10.1016/j.oret.2021.02.008
Im JHB, Jin Y-P, Chow R, Dharia RS, Yan P (2022) Delayed anti-VEGF injections during the COVID-19 pandemic and changes in visual acuity in patients with three common retinal diseases: a systematic review and meta-analysis. Surv Ophthalmol 67:1593–1602. https://doi.org/10.1016/j.survophthal.2022.08.002
doi: 10.1016/j.survophthal.2022.08.002
pubmed: 35970234
pmcid: 9374495
Rush RB, Rush SW (2021) Outcomes in patients resuming intravitreal anti-vascular endothelial growth factory therapy following treatment delay during the coronavirus-19 pandemic. Retina 41:2456–2461. https://doi.org/10.1097/iae.0000000000003276
doi: 10.1097/iae.0000000000003276
pubmed: 34369441
Wecker T, Ehlken C, Bühler A, Lange C, Agostini H, Böhringer D, Stahl A (2017) Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol 101(3):353–359. https://doi.org/10.1136/bjophthalmol-2016-308668
doi: 10.1136/bjophthalmol-2016-308668
pubmed: 27215744
Irini C, Dimitrios K, Christos K, Genovefa M, Eleni D, George T, Panagiotis T, Theodoros NS (2022) The impact of laboratory findings and optical coherence tomography biomarkers on response to intravitreal anti-VEGF treatment in patients with retinal vein occlusion. Int Ophthalmol 42(11):3449–3457. https://doi.org/10.1007/s10792-022-02344-z
doi: 10.1007/s10792-022-02344-z
Karia N (2010) Retinal vein occlusion: pathophysiology and treatment options. Clin Ophthalmol 4:809–816. https://doi.org/10.2147/opth.s7631
doi: 10.2147/opth.s7631
pubmed: 20689798
pmcid: 2915868